Finding treatments for the prevention of dementia is an importantchallenge for medical research.1 Dementia currently affectsabout 4.5 million persons in the United States, and many morehave cognitive impairment. The disorder is characterized byan insidious and progressive loss of memory and higher intellectualfunction, which ultimately leads to the inability of affectedpersons to live independently. The population distribution ofcognitive impairment shows a continuum of severity, with dementiaat one extreme of the distribution.1 Longitudinal, population-basedstudies of people who are 70 years of age or older show thatcognitive function declines abruptly and irreversibly at . . . [Full Text of this Article]
Source Information
From the Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, United Kingdom.
This article has been cited by other articles:
Clarke, R., Birks, J., Nexo, E., Ueland, P. M, Schneede, J., Scott, J., Molloy, A., Evans, J. G.
(2007). Low vitamin B-12 status and risk of cognitive decline in older adults. Am. J. Clin. Nutr.
86: 1384-1391
[Abstract][Full Text]
Hin, H., Clarke, R.
(2007). Reply. Age Ageing
36: 232-232
[Full Text]
Clarke, R.
(2007). Homocysteine-lowering vitamin B supplements do not improve cognitive performance in healthy older adults after two years. Evid. Based Ment. Health
10: 27-27
[Full Text]
Lucca, U., Tettamanti, M., Quadri, P., Dettling, M., Opgen-Rhein, C., Anghelescu, I.-G., Narayan, R. L., Skeaff, C. M., Green, T. J., McMahon, J. A.
(2006). Homocysteine lowering and cognitive performance.. NEJM
355: 1390-1391
[Full Text]